Diligence memo · auto-generated · as of July 2, 2026
VenoStent, Inc.
VenoStent, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
VenoStent, Inc. operates in Other Health Care, based in HOUSTON, TX, USA. Absorbable wrap for blood vessels
Sub-sector tags: Medical Devices, 3D Printing.
Capital & rounds (filed)filed
VenoStent, Inc. has raised $19M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2023-07-05.
Most recent recorded round closed around 2023-07-05.
Valuation (modeled)modeled
Provath models VenoStent, Inc. at approximately $142M (range $38M–$308M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.93× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era. Within the normal band (93% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 3.0 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 7.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 83% of Other Health Care peers (5377 compared).
Modeled value ranks above 84% of those peers.
Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.